Levdobutamine

Levdobutamine
Clinical data
Other names	Levodobutamine; (S)-Dobutamine; LY-206243
Drug class	Sympathomimetic; β1-Adrenergic receptor agonist; Positive inotrope
Identifiers
	IUPAC name 4-[2-[[(2S)-4-(4-hydroxyphenyl)butan-2-yl]amino]ethyl]benzene-1,2-diol;
CAS Number	61661-06-1;
PubChem CID	688441;
ChemSpider	599903;
UNII	0PE6UXH3WG;
ChEBI	CHEBI:59805;
ChEMBL	ChEMBL1367478;
CompTox Dashboard (EPA)	DTXSID90210671 ;
Chemical and physical data
Formula	C18H23NO3
Molar mass	301.386 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H](CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O;
	InChI InChI=1S/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3/t13-/m0/s1; Key:JRWZLRBJNMZMFE-ZDUSSCGKSA-N;

Levdobutamine (INNTooltip International Nonproprietary Name; developmental code name LY-206243; also known as (S)-dobutamine) is a sympathomimetic, selective β₁-adrenergic receptor agonist, and positive inotrope which was never marketed.^[1]^[2] It is the (S)-enantiomer of dobutamine.^[1]

References

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by adding missing information.